Amarin Corp Plc (AMRN)

[Level2Me]

"Europe is a big market opportunity. And we think that the potential 10 plus million patients who might benefit from VASCEPA in Europe, support a sales and commercial infrastructure, and that, in our analysis, comparing to what was available to us from partners that we can make greater value for our shareholders by launching this ourselves and rather than giving up significant piece of the economic to another company who would launch it for us.

We also think that by retaining the rights in Europe, the great – greater optionality for us to be able to consider strategic opportunities both potentially and in multiple [directions] adding products or doing something with a larger company at some point in the future. The market in Europe is large. The approval process is progressing. We do think we're on track for approval in the early part of the coming year. We've hired a very experienced head on the commercial side of things, who has been through this before and knows a lot of people and how to operate within these countries."

(all you knows are omitted)